NeuroSense Therapeutics NRSN

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company specializing in the discovery and development of treatments for neurodegenerative diseases. The company focuses on addressing significant unmet medical needs in conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). NeuroSense Therapeutics leverages a combined therapeutic approach to target multiple disease-related pathways, aiming to slow progression and improve patient outcomes in diseases with limited effective treatment options.

The company generates revenue primarily through the advancement of its lead therapeutic candidate, PrimeC, a novel extended-release oral formulation designed for ALS. PrimeC combines two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed-dose ratio to modulate microRNA synthesis, reduce iron accumulation, and mitigate neuroinflammation. As a clinical-stage entity, NeuroSense Therapeutics currently relies on funding from capital markets, partnerships, and grants to support its research and development activities. Future revenue streams are expected to materialize upon successful regulatory approval and commercialization of PrimeC and other pipeline candidates.

The company operates through the following segments:

• PrimeC for ALS: This segment centers on the development of PrimeC, NeuroSense Therapeutics’ lead candidate for the treatment of ALS. PrimeC has received orphan drug designation from both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as Small and Medium-Sized Enterprise (SME) status from the EMA. The candidate has completed a Phase 2b clinical trial, PARADIGM, demonstrating statistically significant improvements in disease progression, survival rates, and biomarker modulation in ALS patients. The company is preparing for a pivotal Phase 3 trial, expected to enroll approximately 300 patients, with plans to initiate enrollment in the second half of 2025.

• Alzheimer’s Disease Program: This segment focuses on the development of PrimeC for the treatment of Alzheimer’s disease. NeuroSense Therapeutics initiated a Phase 2 clinical trial in late 2023 to evaluate the safety, tolerability, and biological activity of PrimeC in patients with mild to moderate AD. The trial incorporates biomarker analyses using cerebrospinal fluid and blood samples, as well as induced pluripotent stem cells (iPSCs) to assess drug response at the cellular level. Preliminary results have shown positive effects on neuroplasticity and reductions in AD-associated microRNAs, supporting PrimeC’s potential as a disease-modifying therapy.

• Parkinson’s Disease Program: This segment involves the preclinical development of StabiliC, a candidate aimed at treating Parkinson’s disease. NeuroSense Therapeutics is conducting early-stage research to evaluate StabiliC’s ability to address key pathological hallmarks of PD, including protein aggregation and neuroinflammation. The company plans to utilize patient-derived cells and rodent models to further assess StabiliC’s efficacy and mechanism of action.

NeuroSense Therapeutics operates in the highly competitive neurodegenerative disease treatment landscape, where it competes with large pharmaceutical companies, specialty biotechnology firms, and academic institutions. Key competitors in ALS include Biogen, Novartis, Brainstorm Cell Therapeutics, and Clene, among others. In Alzheimer’s disease, the company faces competition from industry leaders such as Biogen, Eli Lilly, Eisai, and Roche. For Parkinson’s disease, competitors include Prothena, Roche, and AstraZeneca. NeuroSense Therapeutics differentiates itself through its multi-target therapeutic approach, which addresses multiple disease pathways simultaneously. The company’s strong patent estate, including method-of-use and formulation patents extending into the 2040s, provides a competitive advantage. Additionally, PrimeC’s orphan drug designation and SME status offer regulatory and financial incentives, positioning the company favorably for potential market exclusivity and expedited approval pathways.

The company’s customer base primarily consists of patients suffering from neurodegenerative diseases, including ALS, Alzheimer’s disease, and Parkinson’s disease. NeuroSense Therapeutics collaborates with clinical trial sites, research institutions, and patient advocacy groups to advance its therapeutic candidates. Specific partnerships include collaborations with Mass General Hospital for biomarker research and NeuroKaire for Alzheimer’s disease studies. Upon commercialization, the company’s products are expected to be prescribed by neurologists and other healthcare providers specializing in neurodegenerative conditions, with reimbursement from public and private payors.